The collaboration will enhance Sanofi's extensive diabetes portfolio and will extend Evotec's metabolic disease and stem cell-based drug discovery programs.

Sanofi could pay Evotec up to EUR300 million ($327.8 million) for hitting various drug development milestones, plus additional royalties on different drugs.
The collaboration will further enhance and complement Sanofi's extensive diabetes portfolio and will extend Evotec's metabolic disease and stem cell-based drug discovery programs.
Source-Medindia